losartan and serine
losartan has been researched along with serine in 3 studies
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bihoreau, C; Clauser, E; Conchon, S; Corvol, P; Curnow, KM; Monnot, C | 1 |
| Fujino, M; Imaizumi, S; Kanazawa, T; Karnik, SS; Kiya, Y; Matsuo, Y; Miura, S; Saku, K | 1 |
| Andreozzi, F; Laino, I; Martino, F; Musca, D; Perticone, F; Perticone, M; Presta, I; Sciacqua, A; Sesti, G; Tassone, EJ | 1 |
Other Studies
3 other study(ies) available for losartan and serine
| Article | Year |
|---|---|
Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding and coupling. Reconstitution of the binding site by co-expression of two deficient mutants.
Topics: Amino Acid Sequence; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Asparagine; Base Sequence; Binding Sites; Biphenyl Compounds; Cell Line; Chlorocebus aethiops; CHO Cells; Cricetinae; DNA Primers; Imidazoles; Inositol Phosphates; Kinetics; Losartan; Molecular Sequence Data; Mutagenesis; Mutagenesis, Site-Directed; Oligodeoxyribonucleotides; Oligopeptides; Point Mutation; Polymerase Chain Reaction; Rats; Receptors, Angiotensin; Recombinant Proteins; Sequence Deletion; Serine; Tetrazoles; Transfection | 1996 |
Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Binding Sites; Chlorocebus aethiops; Computer Simulation; COS Cells; Imidazoles; Losartan; Lysine; Molecular Structure; Mutation; Protein Structure, Secondary; Protein Structure, Tertiary; Rats; Receptor, Angiotensin, Type 1; Serine; Structure-Activity Relationship; Tetrazoles; Valine; Valsartan | 2008 |
Angiotensin II type 1 receptor, but no type 2 receptor, interferes with the insulin-induced nitric oxide production in HUVECs.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Cells, Cultured; Enzyme Activation; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Insulin; Insulin Receptor Substrate Proteins; JNK Mitogen-Activated Protein Kinases; Losartan; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Serine; Signal Transduction; Tyrosine | 2011 |